T. Rowe Price Associates
SGYP

T. Rowe Price Associates’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

T. Rowe Price Associates’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,707
Closed -$147K – 2648
2017
Q3 		$147K Buy
50,707
+100
+0.2% +$341 ﹤0.01% 2461
2017
Q2 		$225K Buy
50,607
+7,400
+17% +$30.5K ﹤0.01% 2333
2017
Q1 		$201K Buy
43,207
+100
+0.2% +$580 ﹤0.01% 2396
2016
Q4 		$263K Hold
43,107
– – ﹤0.01% 2294
2016
Q3 		$238K Sell
43,107
-45,493
-51% -$213K ﹤0.01% 2302
2016
Q2 		$337K Buy
88,600
+37,000
+72% +$125K ﹤0.01% 2119
2016
Q1 		$142K Buy
51,600
+15,900
+45% +$57.6K ﹤0.01% 2364
2015
Q4 		$202K Sell
35,700
-11,300
-24% -$68.9K ﹤0.01% 2300
2015
Q3 		$249K Hold
47,000
– – ﹤0.01% 2209
2015
Q2 		$390K Hold
47,000
– – ﹤0.01% 2099
2015
Q1 		$217K Hold
47,000
– – ﹤0.01% 2328
2014
Q4 		$143K Sell
47,000
-23,000
-33% -$68K ﹤0.01% 2427
2014
Q3 		$195K Buy
70,000
+30,200
+76% +$110K ﹤0.01% 2353
2014
Q2 		$162K Buy
39,800
+18,300
+85% +$77.8K ﹤0.01% 2402
2014
Q1 		$114K Buy
+21,500
New +$121K ﹤0.01% 2417
2013
Q4 		– Sell
-25,350
Closed -$114K – 2527
2013
Q3 		$114K Buy
25,350
+3,042
+14% +$13.6K ﹤0.01% 2376
2013
Q2 		$95K Buy
+22,308
New +$112K ﹤0.01% 2351

Other funds holding SGYP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates's SGYP Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2017, closing a stake of 50,707 shares — an estimated $147K sold.

T. Rowe Price Associates first reported a position in SGYP in Q2 2013 and held it in 17 quarters. The position peaked at $390K in Q2 2015. 149 funds tracked by Wall St. Rank hold SGYP as of Q4 2017.

  • T. Rowe Price Associates reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 50,707 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2017, an estimated $147K.
  • T. Rowe Price Associates first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 17 quarters.
  • T. Rowe Price Associates's Synergy Pharmaceuticals, Inc Common Stock position peaked at $390K in Q2 2015.
  • 149 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.